Inflamalps

Inflamalps is a Swiss biopharmaceutical company focused on the discovery and development of novel topical treatments for chronic inflammatory and anti-microbial diseases, with a primary emphasis on ophthalmology and dermatology. The company's lead candidate, INF101, is a small molecule in pre-clinical development for the topical treatment of dry eye syndrome, including dry eye associated with Sjogren's syndrome, and uveitis. INF101, in-licensed from OncoNOx, acts by inhibiting the production of a key inflammatory cytokine involved in dry eye syndrome. Additionally, Inflamalps is actively engaged in drug discovery efforts to identify novel anti-microbial molecules from microbial extracts to target multi-resistant bacteria and yeasts.